CO.DON: successful General Meeting 2017

15.06.2017 | press release, Aktuell

Teltow/Berlin, 15.06.2017 - This year's annual general meeting of co.don AG (ISIN DE000A1K0227) took place in Berlin on 9 June 2017. In a presentation entitled, 'Agenda 2025 - taking CO.DON forward', Mr Hessel, CEO of the company, first informed the shareholders and proxies present about the financial year 2016 and the company's performance in the first months of the current financial year. '2016 was a successful year for our company overall - CO.DON AG continued on its growth path and successfully refined its business strategy. We have made great progress on the way towards EU approval and have prepared for the tasks ahead by making wide-ranging internal changes.' Hessel continued, 'In financial year 2016 we again reported double-digit revenue growth, but in contrast to prior years when growth was made up of a mix of price increases and product sales, this time it came exclusively from increased transplant sales.' His further comments focused on presenting the strategic options for EU market entry and the general future development of CO.DON AG. The general discussion that followed showed the great interest of those present in the opportunities presented. Positive company news and a buoyant share price ahead of the shareholders' meeting had created a generally positive mood, which also carried over to the event itself.

The voting shareholders attending, who represented 49.26 % of the 17,691,648 million voting shares, approved all the proposals put forward by company management. The members of the Executive Board, Messrs Hessel and Jakobs, and the members of the Supervisory Board were discharged of liability for the financial year 2016; the discharge of liability of Ms Vilma Methner, Executive Board member until mid-2016, was postponed to the next Annual General Meeting due to ongoing litigation. Roever Broenner Susat Mazars GmbH & Co. KG Wirtschaftsprüfungs- und Steuerberatungsgesellschaft, Hamburg, was appointed as auditor for 2017. As the terms of office of Supervisory Board members Professor Hans Bauerfeind, Ms Beatrix Bauerfeind-Johnson and Mr Thomas Krause ended at the close of the shareholders' meeting on 9 June 2017, new elections were necessary. Professor Bauerfeind, Ms Bauerfeind-Johnson and Mr Krause were re-elected to the Supervisory Board for another four years. Other agenda items were the creation of Authorised Capital 2017 and the corresponding changes to the articles of association, authorisation to issue convertible bonds and warrants, creation of a new Authorised Capital 2017 and the corresponding changes to the articles of association at the suggestion of shareholder Thommy Stählin and a resolution on amending section 15 paragraph 1 of the articles of association, 'Supervisory Board remuneration'.

About CO.DON AG: CO.DON AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage in joints following traumatic or degenerative defects. CO.DON condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ('autologous chondrocytes'). CO.DON condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. CO.DON condrosphere® has been used for more than 10 years in over 150 clinics to treat more than 11,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).

More information can be found at www.ihre-zellzuechter.de and www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Director Corporate Communications / IR / PR

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de